Nurix Therapeutics and Roche Ink $2.3B Global Collaboration Deal
Nurix Therapeutics, Inc. has entered into a global License and Collaboration Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (collectively, Roche) for bexobrutideg (NX-5948), an investigational BTK degrader. Under the agreement, Nurix grants Roche an exclusive worldwide license, and Roche will make an upfront payment of $700 million. Nurix is eligible for up to $2.3 billion in total payments, including milestones. The companies will co-develop and co-commercialize bexobrutideg in the U.S., sharing profits and losses equally, while Roche will handle ex-U.S. development and commercialization, with Nurix receiving tiered royalties. Development costs will be shared 40% by Nurix and 60% by Roche.
Key Highlights
- Nurix grants Roche an exclusive worldwide license for bexobrutideg (NX-5948).
- Roche to make an upfront cash payment of $700 million to Nurix.
- Nurix is eligible to receive up to $2.3 billion in total payments, including milestones.
- Development costs will be shared 40% by Nurix and 60% by Roche.
- Nurix and Roche will equally share profits and losses from U.S. commercialization.
- Roche will be responsible for developing and commercializing bexobrutideg outside the U.S.
- Nurix will be eligible to receive tiered royalties from the low teens to high teens on ex-U.S. sales.
Price Impact
More from NRIX